Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background . Atherothrombotic disease, including coronary artery disease (CAD) and peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial infarction, stroke, limb ischemia, heart failure, and CV death. Aim . Evaluate the humanistic and economic burden of CAD and PAD and identify unmet needs through a comprehensive literature review. Methods . Relevant search terms were applied across online publication databases. Studies published between January 2010 and August 2017 meeting the inclusion/exclusion criteria were selected; guidelines were also included. Two rounds of screening were applied to select studies of relevance. Results . Worldwide data showed approximately 5–8% prevalence of CAD and 10–20% prevalence of PAD, dependent on the study design, average age, gender, and geographical location. Data from the REACH registry indicated that 18–35% of patients with CAD and 46–68% of patients with PAD had disease in one or more vascular beds. Use of medication to control modifiable CV risk factors was variable by country (lower in France than in Canada); statins and aspirin were the most widely used therapies in patients with chronic disease. Survival rates have improved with medical advancements, but there is an additional need to improve the humanistic burden of disease (i.e., associated disability and quality of life). The economic burden of atherothrombotic disease is high and expected to increase with increased survival and the aging population. Conclusion . CAD and PAD represent a substantial humanistic and economic burden worldwide, highlighting a need for new interventions to reduce the incidence of atherothrombotic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Baseline characteristics and medication use and clinical outcomes in patients with CAD and PAD from the REACH Registries of (a) Canada,a (b) France,b and (c) Germanyc [1, 2]. aPatients enrolled from January to October 2004; mean age 68.4 ± 9.9. bPercentage of patients experiencing at least one CV event (Figure (a): CAD n = 1356, PAD n = 146; Figure (b): CAD n = 2397, PAD n = 882; Figure (c): CAD n = 3328, PAD n = 1303). cPatients enrolled from December 2003 to June 2014; mean age 69.1–71.7 across risk groups. dPatients enrolled from December 2003 to June 2014; mean age 68.0–69.4 across risk groups. ACE, angiotensin-converting enzyme; ASA, acetylsalicylic acid; CAD, coronary artery disease; CV, cardiovascular; PAD, peripheral artery disease.](https://figures.cochat.ai/paper-figures/5e14fc8ebda846379e697620627d3268/burden-of-coronary-artery-disease-and-peripheral-artery-disease-a-literature-figure-1.jpg)
![Figure 2 The persistent risk of MACE (a) up to 3 years following an index MI (adapted from Blin et al., 2016) [3] and (b) up to 4.5 years following an index MI stratified by age (<72 years old versus ≥72 years old) and risk category (low versus higha) (adapted from Jernberg et al., 2015) [4]. aHigh-risk patients were predefined as those with ≥1 of the following risk factors prior to index; MI: diabetes mellitus, at least one MI prior to index MI event, CABG (proxy for multi-vessel CAD), PAD, stroke, heart failure, or diagnosis of chronic renal dysfunction. CABG, coronary artery bypass graft; CAD, coronary artery disease; CV, cardiovascular; HR, high risk; LR, low risk; MACE, major adverse cardiovascular events; MI, myocardial infarction; PAD, peripheral artery disease.](https://figures.cochat.ai/paper-figures/ef7f32f05aeb4415a5daae684132145b/burden-of-coronary-artery-disease-and-peripheral-artery-disease-a-literature-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mere presence of PAD significantly increases the risk of having atherosclerotic disease in other vascular beds.”
From Racial and Ethnic Disparities in Peripheral Artery Disease (2021) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Approximately, 46% to 68% of patients with PAD also had coronary artery disease (CAD) or cerebrovascular disease.[48][49][50]”
From Racial and Ethnic Disparities in Peripheral Artery Disease (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191 · cited 1×
“These conditions are characterized by progressive (CLI) or sudden onset (ALI) of pain at rest or nonhealing ischemic wounds or gangrene [27, 44, 45] and can ultimately lead to a loss of limbs [46].”
Background2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Kyu, H. H., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32335-3 · Cited by 4,081
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174526 · Cited by 3,708
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Hay, S. I., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32130-x · Cited by 2,083 · cited 1×
“of mortality and morbidity worldwide, atherothrombotic disease places a substantial medical and economic burden on society [7, 12].”
Background2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.007 · Cited by 1,941
Selvin, E., & Erlinger, T. P. (2004) · Circulation · doi:10.1161/01.cir.0000137913.26087.f0 · Cited by 1,885
Fitzmaurice, C., & Global Burden of Disease Cancer Collaboration (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1568 · Cited by 1,646
Bhatt, D. L. (2006) · JAMA · doi:10.1001/jama.295.2.180 · Cited by 1,627 · cited 1×
“, smoking, dyslipidemia, hypertension, and diabetes mellitus) [9].”
One-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Libby, P. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1216063 · Cited by 1,262
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.009 · Cited by 1,021
Jernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M., & Janzon, M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu505 · Cited by 875 · cited 1×
“5 years after an MI (Figures 2(a) and 2(b)) [3, 4].”
BackgroundFihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Diehm, C., Schuster, A., Allenberg, J. R., Darius, H., Haberl, R., Lange, S., Pittrow, D., von Stritzky, B., Tepohl, G., & Trampisch, H.-J. (2004) · Atherosclerosis · doi:10.1016/s0021-9150(03)00204-1 · Cited by 828 · cited 1×
“PAD patients were characterized by high comorbidity (including diabetes, hypertension, and lipid disorders) including other manifestations of atherothrombotic disease [20].”
BackgroundPeripheral artery disease: epidemiology and global perspectives
Fowkes, F. G. R., Aboyans, V., Fowkes, F. J. I., McDermott, M. M., Sampson, U. K. A., & Criqui, M. H. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.179 · Cited by 735
Nehler, M. R., Duval, S., Diao, L., Annex, B. H., Hiatt, W. R., Rogers, K., Zakharyan, A., & Hirsch, A. T. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2014.03.290 · Cited by 502
Howard, D. P. J., Banerjee, A., Fairhead, J. F., Hands, L., Silver, L. E., & Rothwell, P. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016424 · Cited by 318
Mahoney, E. M., Wang, K., Keo, H. H., Duval, S., Smolderen, K. G., Cohen, D. J., Steg, G., Bhatt, D. L., Hirsch, A. T., & on behalf of the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators* (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.930735 · Cited by 256 · cited 1×
“The direct costs associated with PAD are even higher than those for CAD because of the higher rates of polyvascular disease and higher number of annual CV events and hospitalization rates [52].”
BackgroundPathogenesis of the Limb Manifestations and Exercise Limitations in Peripheral Artery Disease
Hiatt, W. R., Armstrong, E. J., Larson, C. J., & Brass, E. P. (2015) · Circulation Research · doi:10.1161/circresaha.116.303566 · Cited by 187 · cited 1×
“Atherosclerosis is highly prevalent and forms the underlying pathophysiology for coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular (CvD)/carotid artery disease [5, 6].”
BackgroundMancini, G. B. J., Gosselin, G., Chow, B., Kostuk, W., Stone, J., Yvorchuk, K. J., Abramson, B. L., Cartier, R., Huckell, V., Tardif, J.-C., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.05.013 · Cited by 166
Epidemiology of peripheral artery disease in Europe: VAS Educational Paper
Olinic, D.-M., Spînu, M., Olinic, M., Homorodean, C., Tataru, D. A., Liew, A., Schernthaner, G.-H., Stanek, A., Fowkes, G. R., & Catalano, M. (2018) · International Angiology · doi:10.23736/s0392-9590.18.03996-2 · Cited by 142 · cited 4×
“A study in Canada confirmed PAD in 8.1% of patients in two prospective study cohorts (N = 1459; average age 63.5 years), based on an ABI ≤0.9 [19].”
BackgroundInfluentialSigvant, B., Kragsterman, B., Falkenberg, M., Hasvold, P., Johansson, S., Thuresson, M., & Nordanstig, J. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2016.03.429 · Cited by 108 · cited 3×
“, 80% of patients with CLI received aspirin within the first 3 months following revascularization [35].”
BackgroundInfluentialLeg symptom categories and rates of mobility decline in peripheral arterial disease
McDermott, M. M., Ferrucci, L., Liu, K., Guralnik, J. M., Tian, L., Liao, Y., & Criqui, M. H. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02941.x · Cited by 90 · cited 1×
“In a single-center US study, patients with asymptomatic PAD or atypical symptoms had greater mobility decline than those without PAD or with symptoms of IC, with a significantly decreased ability to walk for 6 minutes continuously [47].”
BackgroundBraga, M. F. B., Casanova, A., Teoh, H., Dawson, K. G., Gerstein, H. C., FITCHETT, D. H., Harris, S. B., Honos, G. N., McFarlane, P. A., Steele, A., et al. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70393-7 · Cited by 88
Ferrari, R., Abergel, H., Ford, I., Fox, K. M., Greenlaw, N., Steg, P. G., Hu, D., Tendera, M., & Tardif, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.08.013 · Cited by 77
Productivity losses associated with cardiovascular disease: a systematic review
Gordois, A., Toth, P. P., Quek, R. G. W., Proudfoot, E. M., Paoli, C. J., & Gandra, S. R. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2016.1259571 · Cited by 76
Burden of peripheral arterial disease in Europe and the United States: a patient survey
Marrett, E., DiBonaventura, M., & Zhang, Q. (2013) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-11-175 · Cited by 64 · cited 4×
“, pain, functional loss, and loss of limbs) [43].”
BackgroundResultInfluentialSmolderen, K. G., Wang, K., de Pouvourville, G., Brüggenjürgen, B., Röther, J., Zeymer, U., Parhofer, K. G., Steg, P. G., Bhatt, D. L., & Magnuson, E. A. (2012) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2011.09.016 · Cited by 61 · cited 9×
“The average direct medical costs associated with hospitalization for CAD were reported from the REACH registries in France, Germany [2], and Canada [1].”
BackgroundMethodInfluentialSelf-citationThe Direct and Indirect Cost Burden of AcuteCoronary Syndrome
Johnston, S. S., Curkendall, S. M., Makenbaeva, D., Mozaffari, E., Goetzel, R. Z., Burton, W. N., & Maclean, R. (2010) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e31820290f4 · Cited by 58
Smolderen, K. G., Bell, A., Lei, Y., Cohen, E. A., Gabriel Steg, P., Bhatt, D. L., & Mahoney, E. M. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70437-2 · Cited by 57 · cited 6×
“The average direct medical costs associated with hospitalization for CAD were reported from the REACH registries in France, Germany [2], and Canada [1].”
BackgroundMethodInfluentialCost-Effectiveness of Revascularization Strategies
Zhang, Z., Kolm, P., Grau‐Sepulveda, M. V., Ponirakis, A., O’Brien, S. M., Klein, L. W., Shaw, R. E., McKay, C. R., Shahian, D. M., Grover, F. L., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.078 · Cited by 56
Planning secondary prevention: Room for improvement
Beringola, A. C., Fitzsimons, D., Pelliccia, A., Moreno, G., Martín‐Asenjo, R., & Bueno, H. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317704954 · Cited by 45 · cited 1×
“Prognosis can be improved through secondary prevention measures, with lifestyle changes, medicinal control of modifiable CV risk factors, and the prevention of blood clot formation with antithrombotic therapies [11].”
BackgroundRivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
Zannad, F. M., & Bauersachs, R. M. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1636530 · Cited by 44
Self-citationHong, Y., Sebastianski, M., Makowsky, M. J., Tsuyuki, R. T., & McMurtry, M. S. (2016) · Vascular Medicine · doi:10.1177/1358863x16631041 · Cited by 41
Rafie, A. H. S., Stefanick, M. L., Sims, S. T., Phan, T., Higgins, M., Gabriel, A., Assimes, T. L., Narasimhan, B., Nead, K. T., MYERS, J. N., et al. (2010) · Vascular Medicine · doi:10.1177/1358863x10388345 · Cited by 39
Marzolini, S., OH, P. I., Alter, D. A., Stewart, D. E., & Grace, S. L. (2012) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2011.11.034 · Cited by 33
Blin, P., Philippe, F., Bouée, S., Laurendeau, C., Torreton, E., Gourmelin, J., Leproust, S., Lévy-Bachelot, L., & Steg, P. G. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.102 · Cited by 27
Szpakowski, N., Bennell, M. C., Qiu, F., Ko, D. T., Tu, J. V., Kurdyak, P. A., & Wijeysundera, H. C. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002904 · Cited by 24 · cited 1×
“Patients with depression had a higher risk of death and admission for MI compared with those with CAD without depression [40].”
ResultLindgren, H. I. V., Gottsäter, A., Qvarfordt, P. G., & Bergman, S. (2016) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2016.05.004 · Cited by 23
Chase, M. R., Friedman, H. S., Navaratnam, P., Heithoff, K. A., & Simpson, R. J. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.15010 · Cited by 22
Zaninotto, P., Sacker, A., Breeze, E., McMunn, A., & Steptoe, A. (2015) · Aging & Mental Health · doi:10.1080/13607863.2015.1020410 · Cited by 19 · cited 1×
“The observed changes were genderspecific, with women reporting a higher quality of life than men in the 2 and 4 years following a CV event [39].”
Background[Epidemiology of coronary artery disease].
Puymirat, É. (2015) · PubMed · Cited by 17
Stansby, G. P., Mister, R., Fowkes, G. R., Roughton, M., Nugara, F., Brittenden, J., Bradbury, A. W., Ashley, S., Shearman, C. P., Hannon, R., et al. (2011) · Angiology · doi:10.1177/0003319710387917 · Cited by 16
Predictors and Outcomes of Routine Versus Optimal Medical Therapy in Stable Coronary Heart Disease
Chun, S., Qiu, F., Austin, P. C., Ko, D. T., Mamdani, M., Wijeysundera, D. N., Czarnecki, A., Bennell, M. C., & Wijeysundera, H. C. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.05.035 · Cited by 10
Sunderland, M., Jong, M. D., & Bates, D. (2013) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v66i4.1270 · Cited by 6 · cited 1×
“This proportion was higher in patients with concomitant CAD versus those with isolated PAD (78% and 46%, respectively) [36].”
ResultThe evolving nature of coronary artery disease
Steg, P. G., & Dorman, S. (2011) · European Heart Journal Supplements · doi:10.1093/eurheartj/sur018 · Cited by 4 · cited 1×
“Survival rates in patients with CAD have improved; for example, in the USA, age-adjusted mortality between 1980 and 2002 was approximately halved in both male (from 900 to 400 per 100,000) and female (from 500 to 250 per 100,000) patients with CAD [37].”
BackgroundCoronary Artery Disease in French Canadians—Investigation of a Suggested Vulnerable Population
Ayoub, C., Bernick, J., Arasaratnam, P., Chow, J. D. H., Hossain, A., Ruddy, T. D., Hillis, G. S., Kritharides, L., & Chow, B. J. W. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.11.006 · Cited by 4
Research works printed but not linked: 8
- 2017, Heart and Metabolism, 9
- 2015, La Revue Du Praticien, 65, 317
- 2016, Vascular Medicine (United Kingdom), 21, 331
- 2018, International Angiology, 37, 327
- 2016, JACC: Journal of the American College of Cardiology, 69, e71
- 2016, Circulation: Cardiovascular Quality and Outcomes, 9, 731
- 2013, Health and Quality of Life Outcomes, 11
- 2010, Circulation: Cardiovascular Quality and Outcomes, 3, 642
Cited by
Ralapanawa, U., & Sivakanesan, R. (2021) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.201217.001 · Cited by 669
“The risk of dying from CAD rises significantly with aging and systolic blood pressure is the most important modifiable risk factor explaining some additional CAD risks that come about with age [7,16,17].”
Zhou, Y., Zhou, H., Hua, L., Hou, C., Jia, Q., Chen, J., Zhang, S., Wang, Y., He, S., & Jia, E. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.009 · Cited by 249
Mitochondrial Structure and Function in Human Heart Failure
Hinton, A., Claypool, S. M., Neikirk, K., Senoo, N., Wanjalla, C. N., Kirabo, A., & Williams, C. R. (2024) · Circulation Research · doi:10.1161/circresaha.124.323800 · Cited by 220
Wadström, B. N., Wulff, A. B., Pedersen, K. M., Jensen, G. B., & Nordestgaard, B. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab705 · Cited by 234
Racial and Ethnic Disparities in Peripheral Artery Disease
Hackler, E. L., Hamburg, N. M., & White Solaru, K. T. (2021) · Circulation Research · doi:10.1161/circresaha.121.318243 · Cited by 141
Metadata
- Authors
- Bauersachs, R., Zeymer, U., Brière, J.-B., Marre, C., Bowrin, K., & Huelsebeck, M.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Klinikum Ludwigshafen (DE)
- Bayer (Germany) (DE)
- Creativ-Ceutical (France) (FR)
- Bayer (United Kingdom) (GB)
- Corresponding author
- Bauersachs, Rupert
- Venue
- Cardiovascular Therapeutics
- Publisher
- Wiley
- Published
- 2019-11-26
- Volume
- 2019
- Pages
- 1-9
- ISSN
- 1755-5914 (ISSN-L)
- 1755-5922
- PMC
- PMC7024142
- OpenAlex
- W2990657953
- Semantic Scholar
- 7306e92becdce616c64c569876ca723660f04cb3
- Cited by
- 449
- References
- 52
- Citations by year
- 2026: 39 · 2025: 80 · 2024: 118 · 2023: 102 · 2022: 64 · 2021: 38 · 2020: 8
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Therapeutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
- Funders
- Bayer AG
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Epidemiology › Healthcare Systems and Public Health
- Keywords
- coronary artery disease, peripheral arterial disease, atherothrombosis, disease burden, economic burden, humanistic burden, prevalence, quality of life, disability, statins, aspirin, cardiovascular risk management, survival rate, population aging, unmet needs
- MeSH terms
- Aged, Coronary Artery Disease, Female, Health Services Needs and Demand, Humans, Male, Prognosis, Risk Factors, Global Health, Incidence, Prevalence, Health Care Costs, Cost of Illness, Peripheral Arterial Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.